Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Journal: JHEP reports : innovation in hepatology
Published: May 06, 2025
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.
Journal: The Lancet. Digital health
Published: October 01, 2024
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.
Journal: Journal of hepatocellular carcinoma
Published: February 03, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
Journal: Hepatology (Baltimore, Md.)
Published: January 29, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: September 19, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Journal: Journal of hepatology
Published: August 29, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Journal: Frontiers in oncology
Published: December 20, 2022
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Journal: Hepatology international
Published: December 02, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Journal: Cancers
Published: November 01, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 24, 2022
Last Updated: 09/26/2026